Cytokinetics Incorporated [NASDAQ: CYTK] closed the trading session at $15.65 on 10/12/20. The day’s price range saw the stock hit a low of $14.71, while the highest price level was $15.98. The company report on October 8, 2020 that Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure.
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events .
Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death.
The stocks have a year to date performance of 47.50 percent and weekly performance of -45.30 percent. The stock has been moved at 15.50 percent over the last six months. The stock has performed -30.41 percent around the most recent 30 days and changed -43.87 percent over the most recent 3-months.
If compared to the average trading volume of 1.54M shares, CYTK reached to a volume of 3979215 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cytokinetics Incorporated [CYTK]:
Raymond James have made an estimate for Cytokinetics Incorporated shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on July 10, 2020. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on May 05, 2020, representing the official price target for Cytokinetics Incorporated stock. Previously, the target price had yet another raise to $25, while Morgan Stanley analysts kept a Overweight rating on CYTK stock.
The Average True Range (ATR) for Cytokinetics Incorporated is set at 2.42, with the Price to Sales ratio for CYTK stock in the period of the last 12 months amounting to 61.87.
CYTK stock trade performance evaluation
Cytokinetics Incorporated [CYTK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -45.30. With this latest performance, CYTK shares dropped by -30.41% in over the last four-week period, additionally plugging by 15.50% over the last 6 months – not to mention a rise of 39.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYTK stock in for the last two-week period is set at 33.80, with the RSI for the last a single of trading hit 29.84, and the three-weeks RSI is set at 36.39 for Cytokinetics Incorporated [CYTK]. The present Moving Average for the last 50 days of trading for this stock 22.66, while it was recorded at 20.62 for the last single week of trading, and 18.39 for the last 200 days.
Cytokinetics Incorporated [CYTK]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cytokinetics Incorporated [CYTK] shares currently have an operating margin of -367.97. Cytokinetics Incorporated’s Net Margin is presently recorded at -452.93.
Return on Total Capital for CYTK is now -102.20, given the latest momentum, and Return on Invested Capital for the company is -130.67. Return on Equity for this stock declined to -1,622.88, with Return on Assets sitting at -48.58. Additionally, CYTK Total Debt to Total Capital is recorded at 108.74, with Total Debt to Total Assets ending up at 46.95.
Reflecting on the efficiency of the workforce at the company, Cytokinetics Incorporated [CYTK] managed to generate an average of -$780,077 per employee. Receivables Turnover for the company is 4.50 with a Total Asset Turnover recorded at a value of 0.11.Cytokinetics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Earnings per share (EPS) analysis for Cytokinetics Incorporated [CYTK] stock
With the latest financial reports released by the company, Cytokinetics Incorporated posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.49/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -2.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CYTK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cytokinetics Incorporated go to 15.00%.
Cytokinetics Incorporated [CYTK]: Insider Ownership positions
There are presently around $905 million, or 85.50% of CYTK stock, in the hands of institutional investors. The top three institutional holders of CYTK stocks are: BLACKROCK INC. with ownership of 9,361,689, which is approximately 2.592% of the company’s market cap and around 0.80% of the total institutional ownership; VANGUARD GROUP INC, holding 4,571,208 shares of the stock with an approximate value of $71.54 million in CYTK stocks shares; and FMR LLC, currently with $54.91 million in CYTK stock with ownership of nearly 19.654% of the company’s market capitalization.
Positions in Cytokinetics Incorporated stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 92 institutional holders increased their position in Cytokinetics Incorporated [NASDAQ:CYTK] by around 10,263,369 shares. Additionally, 65 investors decreased positions by around 8,125,245 shares, while 18 investors held positions by with 39,455,153 shares. The mentioned changes placed institutional holdings at 57,843,767 shares, according to the latest SEC report filing. CYTK stock had 29 new institutional investments in for a total of 4,944,105 shares, while 16 institutional investors sold positions of 4,253,160 shares during the same period.